The Dow Chemical Company

Biogen Idec Ma Inc.

Cambridge Antibody Technology Limited

Medical Research Council

Medarex Inc.

Biogen, Incorporated

Peregrine Pharmaceuticals, Inc.

Philip Ronald Tempest

Frank J Carr

William Joseph Harris

W H Kerr Anderson

Kathryn Armour

Roy R Lobb

Alison Jane Wilton

Andrew James Williams

Julia Elizabeth Thompson

John Gerald McCafferty

Louise Conroy

Peta Sally Helena Braddock

Helen Jackson

Sarah Leila Du Fou

Thor Las Holtet

Simon Nicholas Lennard

Gregory Paul Winter

Tristan J Vaughan

Kevin Stuart Johnson

Ronald Henry Jackson

Jonathan Alexander Green

Louise Bacon

Raymond Paul Field

Steven Paul Ruddock

The present invention disclosed recombinant anti-VLA-4 antibody molecules, including humanized recombinant anti-VLA-4 antibody molecules. These antibodies are useful in the treatment of specific and non-specific inflammation, including asthma and inflammatory bowel disease. In addition, the humanized recombinant anti-VLA-4 antibodies disclosed can be useful in methods of diagnosing and localizing sites of inflammation.

Recombinant anti-VLA4 antibody molecules

Specific binding members, featuring certain residues of the third CDR of the antibody NH576 (portions of SEQ ID NO:2) are provided, together with their use in methods of treatment and diagnosis.

Specific binding proteins including antibodies which bind to the necrotic centre of tumours, and uses thereof

Treatment for asthma with &#x3b1;4-specific antibodies

Specific binding members comprising human antibody antigen binding domains specific for human transforming growth factor beta (TGF&#x3b2;) bind specifically isoforms TGF&#x3b2;2 and TGF&#x3b2;1 or both, preferentially compared with TGF&#x3b2;3. Specific binding members may be isolated and utilized in the treatment of disease, particularly fibrotic disease and also immune/inflammatory diseases. Therapeutic utility is demonstrated using in vitro and in vivo models. Full sequence and binding information is provided, including epitope sequence information for particularly advantageous specific binding member which binds the active form of TGF&#x3b2;2, neutralizing its activity, but does not bind the latent member.

Human antibodies specific for TGF&#x3b2;2

Treatment for inflammatory bowel disease with &#x3b1;4-specific antibodies

The invention provides specific binding members, for example in the form of antibody variable domains, based on the CDR3 sequences of the antibody VH regions of SL15 (SEQ ID NO:4) and JT182 (SEQ ID NO:10). The antibodies have strong neutralising activity for TGF&#x3b2;and are useful in treating conditions associated with excess TGF&#x3b2;activity, such as fibrosis, immune responses and tumor progression.

[object Object]

Specific binding members, based on the third CDR of the antibody NHS76 (SEQ ID NO: 2) are provided, together with their use in methods of treatment and diagnosis.

Specific binding proteins including antibodies which bind to the necrotic center of tumors, and uses thereof

Novel humanized monoclonal antibodies, humanized antibody fragments, and derivatives thereof which specifically bind TAG-72 are provided as well as methods for their manufacture. These humanized antibodies are useful in the treatment of cancers which express TAG-72 as well as for diagnostic purposes, e.g., for in vivo imaging of tumors or cancer cells which express TAG-72.

High affinity humanized anti-TAG-72 monoclonal antibodies

High affinity humanized anti-Tag-72 monoclonal antibodies

High affinity humanized anti-tag-72 monoclonalantibodies

Recombinant anti-VLA-4 antibody molecules

Humanized antibodies are described which are specific to an Fc receptor (FcR). The humanized antibodies have at least a portion of a complementarity determining region (CDR) derived from a non-human antibody, e.g., murine, with the remaining portions being human in origin. The humanized antibodies can be used therapeutically as is or formulated as bifunctional molecules or immunotoxins.

Humanized antibodies to Fc receptors for immunoglobulin G on human mononuclear phagocytes

Growing community of inventors

West Wratting, United Kingdom

Philip Ronald Tempest